r-SNM System

About Axonics

Axonics, founded in 2012 and headquartered in Irvine, California, established itself as a disruptive force in the sacral neuromodulation (SNM) market with its full-body MRI-compatible, rechargeable implant systems for urinary urgency incontinence and fecal incontinence. Its technology challenged incumbent offerings with a 15+ year battery life and a streamlined implant procedure. Acquired by Boston Scientific in early 2024 for $3.7 billion, Axonics now functions as a key growth asset within Boston Scientific's urology portfolio, leveraging the larger company's global commercial infrastructure to expand access to its advanced neuromodulation therapies.

About Axonics

Axonics, founded in 2012 and headquartered in Irvine, California, established itself as a disruptive force in the sacral neuromodulation (SNM) market with its full-body MRI-compatible, rechargeable implant systems for urinary urgency incontinence and fecal incontinence. Its technology challenged incumbent offerings with a 15+ year battery life and a streamlined implant procedure. Acquired by Boston Scientific in early 2024 for $3.7 billion, Axonics now functions as a key growth asset within Boston Scientific's urology portfolio, leveraging the larger company's global commercial infrastructure to expand access to its advanced neuromodulation therapies.

Therapeutic Areas